Personalis Inc. develops individualized cancer vaccines and other next-generation cancer immunotherapies by providing superior genetic sequencing and analytics capabilities. From nucleic acid extraction to sequencing assays to data analytics, ACE (Accuracy and Content Enhanced) Technology optimizes every step of the next-generation sequencing (NGS) process. Personalis provides high-quality, accurate genetic data to enable biopharma companies to drive their immuno-oncology clinical and biomarker discovery initiatives, allowing for the rational design and development of effective cancer immunotherapies.
PERSONALIS INC Pricing
to get more information.